- Home
- ASTC vs CANF Comparison
ASTC vs CANF Comparison
Compare ASTC & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ASTC | CANF |
|---|---|---|
| Founded | 1984 | 1994 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1M | 5.4M |
| IPO Year | 1995 | N/A |
Fundamental Metrics
Financial Performance| Metric | ASTC | CANF |
|---|---|---|
| Price | $3.14 | $4.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9,750.00 |
| AVG Volume (30 Days) | 11.7K | ★ 74.6K |
| Earning Date | 02-10-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,312,000.00 | $560,000.00 |
| Revenue This Year | N/A | $461.72 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 3.06 | N/A |
| 52 Week Low | $2.47 | $3.36 |
| 52 Week High | $8.01 | $46.60 |
Technical Indicators
Market Signals| Indicator | ASTC | CANF |
|---|---|---|
| Relative Strength Index (RSI) | 34.30 | 65.38 |
| Support Level | $3.04 | $4.00 |
| Resistance Level | $3.40 | $4.32 |
| Average True Range (ATR) | 0.22 | 0.29 |
| MACD | -0.07 | -0.15 |
| Stochastic Oscillator | 1.63 | 39.35 |
Price Performance
Historical ComparisonAbout ASTC Astrotech Corporation (DE)
Astrotech Corp is a science and technology development company. The firm invents, acquires, and commercializes technological innovations sourced from internal research, universities, laboratories, and research institutions. The 1st Detect develops, manufactures, and sells chemical analyzers for use in the airport security, military, and breath analysis markets. AgLAB develops a series of mass spectrometers for use in the agriculture market.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.